American Association for Cancer Research
Browse
epi-23-1034_supplementary_figure_s8_suppsf8.docx (881.79 kB)

Supplementary Figure S8 from Trends of Prostate Cancer Morbidity in Low-Incidence Countries from 1990–2019

Download (881.79 kB)
journal contribution
posted on 2024-02-06, 08:20 authored by Jinjiang Jiang, Bo Chen, Bo Tang, Jie Yang, Ting Zhang, Jinze Li, Daqing Tan, Qiang Wei

Supplementary Figure S8 shows the age-specific burden of prostate cancer among Japan, America in 1990 and 2019.(a) Japan exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 85-89 years age group having the highest ASIR in both years. (b) America exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 75-79 years years age group having the highest ASIR in both years.

Funding

National Natural Science Foundation of China (NSFC)

Science Fund for Distinguished Young Scholars of Sichuan Province (四川省杰出青年科学基金)

History

ARTICLE ABSTRACT

Our study was designed to elucidate the morbidity trends of prostate cancer in low-incidence countries. Data on prostate cancer were extracted from the 2019 Global Burden of Disease study. A cluster analysis of growth rates stratified by age was conducted, and correlation analyses were performed between age-standardized incidence rates (ASIR), estimated annual percent change (EAPC), and socio-demographic index (SDI). Among 35 low-incidence countries for prostate cancer, predominantly located in Asia and North Africa, the SDI ranged from low to high-middle levels. Higher SDI regions exhibited considerably higher ASIR. With the exception of Kyrgyzstan, Kiribati, and Samoa that experienced a decrease in ASIR, the remaining 32 countries displayed an upward morbidity trend since 1990, with all their EAPCs exceeding the global average. In addition, men ages 90 years and above consistently exhibited the highest ASIR for prostate cancer. The most notable growth rate of ASIR was observed in individuals ages 20 to 44 years. Overall, low-incidence countries generally witnessed an increase in prostate cancer morbidity, albeit at levels lower than those seen in Western countries. Individuals ages 90 years and above consistently maintained the highest ASIR since 1990. Notably, more substantial increase of ASIR in younger age was also observed in low-incidence countries. This study offers a comprehensive overview of prostate cancer morbidity in low-incidence countries worldwide from 1990 to 2019. Future research should delve into the associations between incidence, clinical stages, PSA screening, environmental factors, lifestyle, and genetic risk in these low-incidence countries.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC